INSYS Therapeutics, Inc. (INSY) Reaches $6.96 After 9.00% Down Move; 1 Bullish Analysts Covering ITE Group plc (LON:ITE)

June 13, 2018 - By Winifred Garcia

ITE Group plc (LON:ITE) Logo

Among 5 analysts covering ITE Group PLC (LON:ITE), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. ITE Group PLC had 75 analyst reports since October 1, 2015 according to SRatingsIntel. Peel Hunt maintained it with “Hold” rating and GBX 150 target in Thursday, July 13 report. The rating was maintained by Peel Hunt with “Hold” on Tuesday, November 28. The stock has “Hold” rating by Peel Hunt on Monday, October 3. The stock of ITE Group plc (LON:ITE) earned “Buy” rating by Numis Securities on Monday, May 9. Peel Hunt maintained the stock with “Hold” rating in Monday, September 4 report. Peel Hunt maintained the stock with “Hold” rating in Thursday, August 3 report. The firm earned “Reduce” rating on Thursday, January 25 by Peel Hunt. The firm earned “Hold” rating on Monday, October 3 by N+1 Singer. The stock of ITE Group plc (LON:ITE) has “Buy” rating given on Tuesday, November 28 by Numis Securities. Numis Securities maintained the stock with “Buy” rating in Tuesday, April 4 report. See ITE Group plc (LON:ITE) latest ratings:

06/06/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 150.00 Maintain
04/06/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 160.00 New Target: GBX 150.00 Upgrade
15/05/2018 Broker: Peel Hunt Rating: Under Review Under Review
04/05/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 160.00 Maintain
25/04/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 160.00 New Target: GBX 160.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Reduce Old Target: GBX 160.00 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 182.00 New Target: GBX 182.00 Maintain
25/01/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 220.00 New Target: GBX 220.00 Maintain
25/01/2018 Broker: Peel Hunt Rating: Reduce Old Target: GBX 160.00 New Target: GBX 160.00 Maintain
17/01/2018 Broker: Peel Hunt Rating: Reduce Old Target: GBX 160.00 New Target: GBX 160.00 Downgrade

The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) is a huge mover today! The stock decreased 3.85% or $0.28 during the last trading session, reaching $6.96. About 606,919 shares traded or 6.57% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 47.95% since June 13, 2017 and is downtrending. It has underperformed by 60.52% the S&P500. Some Historical INSY News: ; 14/05/2018 – SEVERAL U.S. STATES ALSO JOIN LAWSUITS AGAINST INSYS — COURT FILING; 22/05/2018 – INSYS THERAPEUTICS CONFIRMS OUTCOME OF FDA ADVISORY COMMITTEE M; 30/05/2018 – Minnesota sues opioid maker lnsys over improper drug marketing; 06/04/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Agrima Botanicals; 04/05/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Zenabis; 18/04/2018 – INSYS THERAPEUTICS – PLANS TO ADVANCE CLINICAL RESEARCH OF DRONABINOL INHALATION, ACCEPTED BY U.S. FDA UNDER IND FILING IN H2 2018; 18/04/2018 – INSYS Therapeutics to Advance Clinical Research of Dronabinol lnhalation Using Novel Breath-Actuated Device; 12/04/2018 – ICC Labs Enters Into Term Sheet for Export of Cannabidiol to Sundial in Canada; 16/03/2018 – Five New York doctors charged with taking kickbacks from lnsys; 22/05/2018 – Insys Seeked Approval for Buprenorphine Sublingual Spray as Treatment for Moderate-To-Severe Acute PainThe move comes after 8 months negative chart setup for the $513.78 million company. It was reported on Jun, 13 by Barchart.com. We have $6.33 PT which if reached, will make NASDAQ:INSY worth $46.24 million less.

Analysts await INSYS Therapeutics, Inc. (NASDAQ:INSY) to report earnings on August, 2. They expect $-0.25 earnings per share, down 2,400.00% or $0.24 from last year’s $-0.01 per share. After $-0.22 actual earnings per share reported by INSYS Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 13.64% negative EPS growth.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Seekingalpha.com which released: “A Buvaya Failure Could Sting Insys” on May 18, 2018, also Seekingalpha.com with their article: “Insys Continues To Tread Water” published on May 16, 2018, Globenewswire.com published: “INSYS Therapeutics to Present at Jefferies Global Healthcare Conference” on June 04, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Fool.com and their article: “Better Marijuana Stock: Insys Pharmaceuticals vs. Cara Therapeutics” published on May 19, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: May 18, 2018.

Among 7 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Insys Therapeutics had 23 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. On Tuesday, July 25 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was maintained by RBC Capital Markets with “Buy” on Monday, October 9. The company was maintained on Friday, November 3 by Jefferies. RBC Capital Markets maintained it with “Buy” rating and $1600 target in Thursday, June 1 report. Oppenheimer maintained the shares of INSY in report on Tuesday, August 4 with “Hold” rating. Jefferies maintained it with “Buy” rating and $18 target in Monday, October 10 report. The firm earned “Outperform” rating on Thursday, September 22 by RBC Capital Markets. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) earned “Buy” rating by RBC Capital Markets on Thursday, August 3. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) has “Buy” rating given on Friday, October 27 by RBC Capital Markets.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $513.78 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

Since February 21, 2018, it had 0 insider buys, and 1 insider sale for $1.07 million activity. Tambi Brian sold 166,504 shares worth $1.07M.

Investors sentiment decreased to 0.75 in 2018 Q1. Its down 0.01, from 0.76 in 2017Q4. It is negative, as 14 investors sold INSYS Therapeutics, Inc. shares while 30 reduced holdings. 11 funds opened positions while 22 raised stakes. 12.41 million shares or 24.49% less from 16.43 million shares in 2017Q4 were reported. Morgan Stanley reported 75,406 shares stake. Gam Hldg Ag has invested 0.02% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Credit Suisse Ag stated it has 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Dekabank Deutsche Girozentrale reported 29,000 shares stake. Moreover, Meeder Asset has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Legal & General Gp Pcl, a United Kingdom-based fund reported 5,528 shares. Eqis Cap Mgmt Inc invested 0.02% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Sfmg Ltd Liability Corporation holds 11,994 shares or 0.01% of its portfolio. Fmr Ltd Liability reported 242,764 shares or 0% of all its holdings. Winslow Evans & Crocker Inc has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Rhumbline Advisers holds 23,930 shares or 0% of its portfolio. 740 were accumulated by Alphamark Advisors Ltd Liability Company. Jpmorgan Chase Communications has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Moreover, Bridgeway Cap has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Orbimed Advsrs Ltd Limited Liability Company owns 0.26% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 3.51 million shares.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>